Controlled trial of slowing of Kidney Disease progression From the Inhibition of Xanthine oxidase (CKD-FIX): A double-blind, randomised, placebo-controlled trial [ 2013 - 2018 ]

Also known as: CKD-FIX: a randomised, controlled trial of allopurinol in the slowing of kidney disease progression

Research Grant

[Cite as]

Researchers: Prof David Johnson (Principal investigator) ,  A/Pr Gopala Rangan A/Pr John Kanellis A/Pr Sunil Badve Dr Fiona Brown
View all 10 related researchers

Brief description Chronic kidney disease (CKD) is a major public health problem affecting over 1.5 million Australians and is associated with increased risk of death, heart disease and progression to end-stage kidney disease (ESKD). Current treatments to slow progression to ESKD are limited. The CKD-FIX trial aims to find out whether treatment with allopurinol, a commonly used drug for gout prevention, safely and effectively slows CKD progression. This could lead to significant health and economic benefits.

Funding Amount $AUD 2,019,452.44

Funding Scheme Project Grants

Notes Standard Project Grant

Viewed: [[ro.stat.viewed]]